Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but how they signal in that context is less well characterized than in carcinomas. To uncover novel RAS biology and potential therapeutic vulnerabilities, we employed a multi-omics screening approach in multiple myeloma to ide...
ORGANISM(S): Homo sapiens